Volume 7 Supplement 6

23rd European Society for Animal Cell Technology (ESACT) Meeting: Better Cells for Better Health

Open Access

Scale-up considerations for monoclonal antibody production process: an oxygen transfer flux approach

BMC Proceedings20137(Suppl 6):P49


Published: 4 December 2013


When scaling up a monoclonal antibody (mAb) production process in stirred tank bioreactor, oxygen transfer is probably one of the most challenging parameters to consider. Approaches such as keeping constant specific power input or tip speed across the scales are widely described in the literature and are often based on the assumption that mammalian cells are sensitive to shear stress.

However, with the high cell densities reached in modern processes, such scale-up strategies can lead to relatively high gas flow rate to compensate low agitation speed which could be detrimental to cells in its own right.

As an alternative, we explored a scale-up strategy based on the overall oxygen transfer flux (OTF) required by the cell culture process. OTF was defined as directly proportional to oxygen transfer coefficient (kLa) and oxygen enrichment in the gas mix. This way the overall gas flow can be kept at relatively low values, while satisfying the oxygen requirements of a high cell density culture.

Materials and methods

Process scale-up between 3 different stirred tank bioreactors was studied: a 2 L glass bioreactor (Sartorius Stedim Biotech) equipped with one 3-segment blade impeller, a 10 L glass bioreactor (Sartorius Stedim Biotech) equipped with two 3-segment blade impellers and a 80 L stainless steel bioreactor (Zeta Biopharma) equipped with two elephant ear impellers.

Oxygen transfer coefficients (kLa) were determined for the chemically defined production medium, using the dynamic technique of oxygen adsorption. The statistical analysis software JMP (SAS) was then used in order to express kLa's according to the following equation: kLa = A * (P/V) α * Vsβ, P/V being volumetric power input [W.m-3] and Vs being superficial air velocity [m.s-1], and to analyze our results.

Oxygen transfer flux was defined as followed: OTF = kLa * (%O2 in the gas mix/% O2 in air).

For cell culture experiments, bioreactors were inoculated with a CHO cell line producing a mAb. Cells were cultivated in chemically defined media for a 14-day fed-batch process. The culture was controlled to maintain the desired process parameters (temperature, pH, dO2 and glucose concentration). dO2 level was maintained using a cascade aeration. Viable cell density (VCD) and viability were monitored by Trypan blue dye exclusion using a Vicell XR (Beckman Coulter). Glucose and lactate concentrations were determined using a Nova Bioprofile 400 analyzer (Nova Biomedical). Offline dissolved CO2 and osmolality were measured with a Nova Bioprofile pHox (Nova Biomedical) and Osmo 2020 (Advanced Instrument) analyzers respectively. mAb concentrations were determined by Protein A HPLC.


kLa mapping of 2 L, 10 L and 80 L bioreactors

The 2 L and 10 L bioreactors were characterized for a range of superficial gas velocity going from 5.0 × 10-5 to 4.0 × 10-4 m.s-1 and the 80 L for a range going from 2.0 × 10-4 to 1.2 × 10-3 m.s-1. Specific power input was ranged from 10 to 90 W.m-3 for the 2 L bioreactor, 20 to 130 W.m-3 for the 10 L bioreactor and 5 to 80 W.m-3 for the 80 L bioreactor. Models were generated with JMP and gave the following equations for kLa [s-1]:

2 L bioreactor: kLa = 6.37 × 10-2 * (P/V)0.28 * Vs0.59 (R2 = 0.98, Prob>F: <0.0001)

10 L bioreactor: kLa = 4.07 × 10-2 * (P/V)0.55 * Vs0.67 (R2 = 0.91, Prob>F: <0.0001)

80 L bioreactor: kLa = 5.53 × 10-2 * (P/V)0.72 * Vs0.77 (R2 = 0.92, Prob>F: <0.0001)

Scale-up of aeration and agitation strategy of a monoclonal antibody production process using a constant OTF approach

The cell culture process was initially developed at 2 L and 10 L scale. Maximum Oxygen Transfer Flux was determined at maximum cell density for these two scales. This maximum OTF was kept constant for scaling up to 80 L (Table 1). From kLa mapping of the 80 L bioreactor, appropriate P/V, Vs and O2% values were chosen in order to reach the target OTF.
Table 1

Determination of aeration and agitation strategy in the 80 L bioreactor, based on the maximum OTF required by the cells at 2 L and 10 L scales.


2 L

10 L


80 L

P/V [W.m -3 ]





Vs [×10 -4 m.s -1 ]





k L a [×10 -3 s -1 ]





%O 2 in gas mix





OTF max [×10 -3 s -1 ]



Target OTF for 80 L

= 10 L OTF


To confirm that high specific power input are well tolerated by CHO cells, the fed-batch process was first run in two 2 L bioreactors (Figure 1a). Agitation speed was set at 250 rpm (20 W.m-3) in the first bioreactor and at 400 rpm (90 W.m-3) in the second bioreactor. In the high agitation condition, the maximum VCD was 1.8-fold higher, viability remained above 80% (versus 60% in the low agitation condition) and mAb titer was 2.2-fold higher.
Figure 1

Cell culture process performance at 2 L, 10 L and 80 L scale. a) Impact of agitation speed on VCD and mAb titer at 2 L scale. b) Comparison of VCD, viability and mAb titer obtained in 2 L, 10 L and 80 L bioreactors. c) Comparison of osmolality, glucose and lactate profiles obtained in 2 L, 10 L and 80 L bioreactor. d) Online pH and dCO2 levels obtained in 2 L, 10 L and 80 L bioreactors.

Our model fed-batch process was then run in our 80 L bioreactor, using the aeration strategy defined in Table 1. Figure 1b, c and 1d show that the process was successfully scaled-up from 2 L and 10 L to 80 L bioreactor.


Thanks to extensive characterization of aeration conditions in 2 L, 10 L and 80 L bioreactors, the oxygen transfer flux approach enabled to have a sufficient aeration and comparable process performance across the scales, including dCO2 profile. The same strategy will be used for further scale-up of the process to 2000 L. However, the results also revealed that our 2 L scale model should be re-assessed to become more predictive of 10 L and 80 L scales.



This work was carried out within the Cell Culture Process Sciences laboratories of UCB Pharma SA, Braine l'Alleud, Belgium.

Authors’ Affiliations

BioTech Sciences, UCB Pharma SA


© Gimenez et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.